Case series shows effective treatment of solar lentigines with a green laser in five patients, indicating promising results.
Background: Solar lentigines are common epidermal hyperpigmented macules associated with chronic ultraviolet exposure and photoaging. Objective: To describe a standardized 532 nm green laser protocol for solar lentigines and to place these observations within a narrative review with a structured PubMed/Medline literature search. Methods: Five patients (two women and three men; age range 42–65 years, mean 53.6 years; Fitzpatrick skin phototypes II–III) with solar lentigines underwent treatment with a 532 nm green laser (QuadroStarPRO GREEN, Asclepion) using a standardized, single-session protocol. Outcomes were assessed at the final available follow-up (day 21) by 2 independent dermatologists using a retrospective categorical response classification (complete response/partial response/no response) based on paired baseline and day 21 image documentation only; patient satisfaction was recorded at day 21 on a 0–10 visual analog scale (VAS). A narrative review with a structured PubMed/Medline literature search was conducted to identify clinical studies evaluating 532 nm KTP/green laser devices for lentigines, freckles, and ephelides. Results: All five target lesions were classified as complete response at day 21 (5/5 complete response), with a mean VAS satisfaction score of 8.6/10 (range, 7–10) and no discordance between dermatologists. Mild transient erythema was observed immediately after treatment and improved within the first day; no persistent adverse events, dyschromia, or scarring were observed during the available 21-day follow-up. Conclusions: In this small case series, a single-session millisecond 532 nm green laser protocol was associated with complete-response classification at day 21 in five target lesions. Published clinical studies indicate that outcomes with 532 nm devices vary with device type, pulse structure, and treatment settings; larger comparative studies with objective pigment measures and longer follow-ups are needed.
No takes yet. Share an insight, caveat, or question.
Zappia et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: